News
Chinese trial backs base-editing drug for thalassaemia
A landmark study in China has shown that a base-editing therapy developed by CorrectSequence achieved stellar results in beta-thalassaemia.
News
Roche places a $1bn bet on C4T degrader-antibody conjugates
Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.
News
Pulmonary fibrosis drug developer Avalyn files IPO
Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.
News
23andMe study explains variable results with obesity drugs
Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.
News
Syneron raises $150m for macrocyclics, and other financings
Our round-up of recent biotech venture capital financings includes nine-figure rounds for Syneron, Stipple Bio, and Sidewinder.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
